Oxford BioDynamics Plc
("OBD" or the "Company" and, together with its subsidiaries, the "Group")
PDMR Dealing
3 November 2023 - Oxford BioDynamics Plc (AIM: OBD) announces that it has received notice that on 2 November 2023, Non-Executive Chairman, Matthew Wakefield, transferred 94,000 ordinary shares of 1 pence each ("Ordinary Shares") into his ISA. The transfer was effected through a sale of 94,000 Ordinary Shares at 33.75p and the repurchase of 94,000 Ordinary Shares at 33.80p into his ISA. On the same day, Matthew Wakefield also transferred 200,000 Ordinary Shares to his wife, Mrs Carla Wakefield, for nil consideration.
Following these transactions, Matthew Wakefield remains beneficially interested in a total of 1,022,727 Ordinary Shares, representing approximately 0.70% of the Company's current issued share capital.
The notification below, made in accordance with the requirements of UK Market Abuse Regulation, provides further details:
| 1 | Details of the person discharging managerial responsibilities/person closely associated | |||||||||||||
| a) | Name | Matthew Wakefield | ||||||||||||
| 2 | Reason for the notification | |||||||||||||
| a) | Position/status | Director/PDMR | ||||||||||||
| b) | Initial notification/ Amendment | Initial notification | ||||||||||||
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||||||||||
| a) | Name | Oxford BioDynamics Plc | ||||||||||||
| b) | LEI | 2138005Y1TK258O5U928 | ||||||||||||
| 4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||||||||||
| a) | Description of the financial instrument, type of instrument Identification code | Ordinary Shares of 1 pence each
ISIN: GB00BD5H8572 | ||||||||||||
| b) | Nature of the transaction | Transfer of shares into ISA through sale and re-purchase of 94,000 Ordinary Shares In specie spousal transfer of 200,000 Ordinary Shares | ||||||||||||
| c) | Price(s) and volume(s) |
| ||||||||||||
| d) | Aggregated information - Aggregated volume - Price | n/a
| ||||||||||||
| e) | Dates of the transactions | 2 November 2023 | ||||||||||||
| f) | Place of the transaction | London Stock Exchange (XLON) (sale and re-purchase) | ||||||||||||
-Ends-
For further details please contact:
| Oxford BioDynamics Plc Jon Burrows, CEO Paul Stockdale, CFO
| Tel: +44 (0)1865 518910 |
| Shore Capital - Nominated Adviser and Broker Stephane Auton / Iain Sexton
| Tel: +44 (0)20 7408 4090 |
| Instinctif Partners Melanie Toyne-Sewell / Rozi Morris / Jack Kincade | Tel: +44 (0)20 7457 2020 OxfordBioDynamics@instinctif.com
|
Notes for Editors
About Oxford BioDynamics Plc
Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.
Its flagship products are the EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) and EpiSwitch® PSE (EpiSwitch Prostate Screening test) blood tests. CiRT is a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022. PSE is a blood test that boosts the predictive accuracy of a PSA test from 55% to 94% when testing the presence or absence of prostate cancer, which has been launched in the US and UK in September 2023.
In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit, which is available for purchase by the life science research community.
The Company's product portfolio is based on a proprietary 3D genomic biomarker platform, EpiSwitch®, which can build molecular diagnostic classifiers for the prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.
Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.
The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 15,000 samples in more than 30 human diseases.
OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg and a clinical laboratory in Frederick, MD, USA, and a reference laboratory in Penang, Malaysia.
For more information, please visit the Company's website, www.oxfordbiodynamics.com, or follow OBD on Twitter (@OxBioDynamics) and LinkedIn.
About EpiSwitch®
The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch® can be used to diagnose patients or determine how individuals might respond to a disease or treatment.
Built on over 10 years of research, EpiSwitch® is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 15,000 samples in 30 disease areas, and reduced to practice.
In addition to stratifying patients with respect to anticipated clinical outcomes, EpiSwitch® data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
